Figure legends

Figure 1a. Mean percent of predicted FVC before infliximab treatment and at follow-up in responders (n=10) and non-responders (n=2).
Figure 1b. Mean percent of predicted DLCO before infliximab treatment and at follow-up in responders (n=10) and non-responders (n=2).
Figure 2a. CD4/CD8 before infliximab treatment and at follow-up. Each line denotes one patient.
Figure 2b. Number of mast cells per 10 visual fields in x16 magnification before infliximab treatment and at follow-up. Each line denotes one patient.
Figure 2c. Cell concentration before infliximab treatment and at follow-up. Each line denotes one patient.
Figure 2d. Percentage of lymphocytes before infliximab treatment and at follow-up.
Each line denotes one patient.
Figure 2e. Number of lymhocytes/106 l before infliximab treatment and at follow-up. Each line denotes one patient.
Figure 2f. Percentage of CD4+ T-cells expressing CD69 before infliximab treatment and at follow-up. Each line denotes one patient.
Figure 2g. Percentage of CD4+ T-cells expressing FoxP3 before infliximab treatment and at follow-up. Each line denotes one patient.

Figures